To neutralize ERBB2 we employed two anti-ERBB2 humanized monoclonal antibodies, namely trastuzumab and pertuzumab, currently used in clinics to treat HER2+ breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.